Layman RM, Han HS, Rugo HS, Stringer-Reasor EM, et al. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. Lancet Oncol 2024;25:474-487.
PMID: 38547892